Search
AVXS-301
go.drugbank.com/drugs/DB17943ExperimentalIt is being investigated for the treatment of Amyotrophic Lateral Sclerosis (ALS).[L47077]
LX-7101
go.drugbank.com/drugs/DB16009InvestigationalLX-7101 is under investigation in clinical trial NCT01528111 (Study to Evaluate the Safety, Tolerability, and Efficacy of LX7101 in Subjects With Primary Open-angle Glaucoma or Ocular Hypertension).
Salts: LX-7101 hydrochlorideGlypromate
go.drugbank.com/drugs/DB05633ExperimentalNeuren Pharmaceuticals was developing Glypromate (glycine-proline glutamate), a naturally occurring small-molecule neuroprotectant derived from IGF-1 which inhibits caspase III dependent apoptosis, for
Synonyms: Gly-pro-gluLaquinimod
go.drugbank.com/drugs/DB06685InvestigationalIt is currently under development in phase III trials for treatment of multiple sclerosis as an oral therapy, like fingolimod.
Carumonam
go.drugbank.com/drugs/DB13553ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBrodimoprim
go.drugbank.com/drugs/DB13795ExperimentalCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic UseBamipine
go.drugbank.com/drugs/DB13489InvestigationalBamipine is a first-generation antihistamine.
Categories: Antihistamines for Systemic Use, Antihistamines for Topical UsePradofloxacin
go.drugbank.com/drugs/DB11453ExperimentalVet approvedIt was approved by the European Commission in April 2011 for bacterial infections in dogs and cats. … Pradofloxacin is a 3rd generation fluoroquinolone antibiotic developed by Bayer HealthCare AG, Animal Health GmBH.
Inarigivir
go.drugbank.com/drugs/DB15062InvestigationalInarigivir is under investigation in clinical trial NCT03434353 (Study to Evaluate the Antiviral Activity of Inarigivir (GS-9992) Plus Tenofovir Alafenamide (TAF) for 12 Weeks in Adults With Chronic Hepatitis
CX-2009
go.drugbank.com/drugs/DB16090InvestigationalCX-2009 is under investigation in clinical trial NCT03149549 (PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors).